Profil
Michel Afargan is the founder of Israeli Consortium of Pharmalogica.
He is currently the Chief Executive Officer at LifeWave Ltd.
since 2010.
Previously, he worked as Vice President-Strategic Development at Intec Pharma Ltd.
from 2004 to 2007.
He also served as Head-Pharmaceutical Development at Aspireo Pharmaceuticals Ltd.
Dr. Afargan has a graduate and doctorate degree from The Hebrew University of Jerusalem and an undergraduate and graduate degree from Ben-Gurion University of the Negev.
Postes actifs de Michel Afargan
| Sociétés | Poste | Début |
|---|---|---|
LifeWave Ltd.
 LifeWave Ltd. Medical SpecialtiesHealth Technology LifeWave Ltd. engages in the development and manufacture of a medical device for the treatment of chronic wounds. The company was founded on May 24, 2000 and is headquartered in Petach-Tikva, Israel. | Directeur Général | 01/11/2007 |
Anciens postes connus de Michel Afargan
| Sociétés | Poste | Fin |
|---|---|---|
Intec Pharma Ltd.
 Intec Pharma Ltd. Pharmaceuticals: MajorHealth Technology Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel. | Corporate Officer/Principal | 01/01/2007 |
Aspireo Pharmaceuticals Ltd.
 Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Corporate Officer/Principal | - |
| Israeli Consortium of Pharmalogica | Fondateur | - |
Formation de Michel Afargan
| Ben-Gurion University of the Negev | Graduate Degree |
| The Hebrew University of Jerusalem | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
LifeWave Ltd.
LifeWave Ltd. Medical SpecialtiesHealth Technology LifeWave Ltd. engages in the development and manufacture of a medical device for the treatment of chronic wounds. The company was founded on May 24, 2000 and is headquartered in Petach-Tikva, Israel. | Health Technology |
| Israeli Consortium of Pharmalogica | |
Intec Pharma Ltd.
Intec Pharma Ltd. Pharmaceuticals: MajorHealth Technology Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel. | Health Technology |
Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Health Technology |
